top of page

PSAAI

PATHOGEN-SPECIFIC IMMUNOMODULATORS

01

INTRAVENOUS IMMUNOGLOBULIN (IVIG) (UPDATED)

02

CONVALESCENT PLASMA (UPDATED)

03

HYPERIMMUNE GLOBULIN (UPDATED)

NON-PATHOGEN-SPECIFIC IMMUNOMODULATORS

01

ACE INHIBITORS AND ANGIOTENSIN II

RECEPTOR BLOCKERS

02

ALPHA 1 ADRENERGIC RECEPTOR ANTAGONISTS

03

04

05

06

AZITHROMYCIN (UPDATED)

07

BCG VACCINE (UPDATED)

08

CALCINEURIN INHIBITORS

09

10

CORTICOSTEROIDS

(UPDATED)

11

HYDROXYCHLOROQUINE (HCQ) AND CHLOROQUINE (CQ) (UPDATED)

12

INOSINE PRANOBEX

13

INTERFERON AND INTERFERON INHIBITORS (UPDATED)

14

TARGETED MONOCLONAL ANTIBODIES

15

MESENCHYMAL STEM (STROMAL) CELLS (UPDATED)

16

RELEASE ACTIVE ANTIBODIES TO HUMAN INTERFERON GAMMA

17

STATINS (UPDATED)

18

NEW IMMUNOMODULATORS REVIEWED FOR THE 3RD VERSION

01

ANTI-COAGULANTS (HEPARIN AND ITS DERIVATIVES)

02

03

04

H2 RECEPTOR BLOCKERS (FAMOTIDINE)

05

MYCOPHENOLATE MOFETIL

06

VIRGIN COCONUT OIL (LAURIC ACID)

CONCLUDING
REMARKS

01

AUTHORS & THEIR ACADEMIC POSITION

OR HOSPITAL AFFILIATION

02

AVAILABILITY OF THE IMMUNOMODULATORS

IN THE PHILIPPINES

03

TABLES OF PUBLISHED STUDIES

Review Of Immunomodulators

(Full PDF)

Version 4.2 (August 15, 2021)

bottom of page